Guardant Health grows with Shield blood CRC screening, Quest deal, 50M reach, 335% surge, and FY25 revenue $981M up 33%. Read ...
Active-duty service members and eligible family members now have access to blood test for colorectal cancer screening with no copay PALO ALTO, Calif., January 08, 2026--(BUSINESS WIRE)--Guardant ...
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.’s (NASDAQ:GH) Shield blood test for colorectal ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the National Cancer Institute (NCI) has selected the company’s Shield™ ...
Strategic partnership will expand Shield to PathGroup’s 15,000+ primary care and OBGYN physicians PathGroup’s extensive network of phlebotomists and Patient Service Centers enables easier access to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results